Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) fell 3.8% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.26, with a volume of 120,841 shares traded. The stock had previously closed at $3.39.

A number of brokerages have issued reports on DRNA. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 25th. Chardan Capital reduced their price objective on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a research report on Monday, August 15th. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Friday, August 5th. Leerink Swann reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Thursday, June 30th. Finally, Stifel Nicolaus reduced their price objective on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, June 30th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $11.85.

The company’s market capitalization is $65.37 million. The firm’s 50-day moving average price is $3.35 and its 200-day moving average price is $4.15.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.09. On average, analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.17) earnings per share for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.